#United States #New Orleans #Ambrosia Biosciences #ADA Scientific Session #AMB-702

Ambrosia Biosciences Presents at ADA 86th Scientific Session

Ambrosia Biosciences Inc., a promising player in the pharmaceutical industry, recently announced its participation in the upcoming 86th Scientific Session of the American Diabetes Association (ADA). This highly-anticipated conference is scheduled to take place from June 5 to June 8, 2026, in the dynamic city of New Orleans, LA.

As part of their participation, Ambrosia will unveil a late-breaking poster presentation that spotlights their innovative development candidate, AMB-702, which is a novel oral small molecule GLP-1 receptor agonist. This presentation is set to provide critical insights into the preclinical profile of AMB-702, particularly its pharmacokinetic properties and the encouraging in vivo efficacy results.

Innovative Approach to Metabolic Health

The significance of this development lies in the ongoing need for next-generation therapies to address metabolic disorders, such as obesity and type 2 diabetes. According to Dr. Patrice Lee, the President of Research and Development at Ambrosia, there is a substantial opportunity in the market for oral small molecule GLP-1 receptor agonists with unique characteristics that potentially complement existing therapeutic regimens.

Presentation Highlights

The details of the presentation are as follows:

• - Title: Nonclinical profile of AMB-702, a Potent and Novel Oral GLP-1 Receptor Agonist
• - Poster Number: 3065-LB
• - Session: Late-breaking poster session, Poster Halls D-E
• - Date: Sunday, June 7, 2026
• - Time: 12:30 PM – 1:30 PM CT

This session represents not only an opportunity for Ambrosia to share its findings but also for scientists, healthcare providers, and industry stakeholders to glean insights that could shape future treatment options.

About Ambrosia Biosciences Inc.

Ambrosia Biosciences, headquartered in Boulder, Colorado, is a privately held company committed to developing innovative therapies for obesity and other related metabolic disorders. By focusing on orally delivered, small molecule therapies, Ambrosia aims to streamline treatment regimens for patients struggling with metabolic issues. For more information on their research and developments, visit Ambrosia Biosciences.

As the ADA session approaches, the diabetes and metabolic health community eagerly awaits Ambrosia's groundbreaking presentation. This event not only highlights the company's innovative spirit and commitment to combating metabolic disorders but also showcases the potential for AMB-702 to become a key player in the clinical landscape.

Looking Ahead

The expectations surrounding Ambrosia’s presentation are high, marking a critical moment not just for the company, but for all stakeholders invested in the fight against diabetes and obesity. The company is poised to make a significant impact, given the latest advancements in its research and development pipeline.

With a focus on patient-centric approaches in treatment and therapy, Ambrosia’s continued commitments could lead to groundbreaking advancements in the field of metabolism and healthcare.